Novo vs. KBP: How a $1.3B deal turned into an international legal fight

CRO

VanNaarden
Favicon Fierce Biotech

Lilly oncology head weighs in on FDA cancer drug policies

Lilly’s oncology chief, Jake Van Naarden, suggested that the FDA's policies on clinical trial crossover and high U.S. enrollment are not compatible.
Angus Liu Oct 21, 2025 11:53am
Novo
Favicon Fierce Biotech

Novo Nordisk vs KBP: From $1.3B deal to legal battlefield

Oct 2, 2025 3:00am